On April 9, 2021, the recombinant new coronavirus vaccine of the China National Institute of Biological Research of Sinopharm Group obtained the clinical trial approval from the National Medical Products Administration.
This is the new crown vaccine of another technical route after the two new inactivated vaccines of Sinopharm Sinopharm, and it has become China's third new crown vaccine.
The recombinant new coronavirus vaccine is based on the natural structural characteristics of the new coronavirus spike protein (S protein) receptor binding region (RBD), and uses structural biology and computational biology to independently design and develop, and uses genetic engineering technology to construct engineered cell lines and recombinant expression Antigen protein, clear target, strong pertinence.
After immunization, it can induce the body to produce targeted neutralizing antibodies, thereby blocking the combination of the virus and the recipient cells and exerting a protective effect.
China Biotech stated that the genetic recombinant protein vaccine has a mature technology route and is suitable for large-scale production.
Live viruses and other infectious materials are not involved in the whole preparation process, and it does not need to be carried out in a high-grade biosafety environment.